Research Note: Evaluation of boric acid as a chemoprophylaxis candidate to prevent histomoniasis

L C Beer1, C N Vuong1, T L Barros1

  • 1University of Arkansas: Division of Agriculture, Poultry Science Department, Fayetteville, AR 72701, USA.

Poultry Science
|April 4, 2020
PubMed

Insights

Boric acid (BA) did not prevent or reduce histomoniasis in turkeys. This study found no significant differences in mortality or lesion severity between turkeys fed BA and those in the control group.

Area of Science:

  • Veterinary Medicine
  • Parasitology
  • Animal Science

Background:

  • Histomoniasis, caused by *Histomonas meleagridis*, is a significant disease in turkeys.
  • Currently, no effective chemoprophylaxis options exist for histomoniasis.
  • Boric acid (BA) has demonstrated antifungal, antiseptic, and antiviral properties.

Purpose of the Study:

  • To evaluate the efficacy of dietary boric acid (BA) as a chemoprophylaxis against histomoniasis in turkeys.
  • To determine if BA supplementation can mitigate disease severity following challenge with *Histomonas meleagridis*.

Main Methods:

  • Turkey poults were fed either a basal diet or a diet supplemented with 0.2% boric acid.
  • Challenged groups were inoculated with *H. meleagridis*.
  • Body weight gain, mortality, and lesion development were assessed postchallenge.

Main Results:

  • Boric acid supplementation resulted in lower body weight gain both pre- and post-challenge compared to control groups.
  • No statistically significant differences were observed in mortality rates or the severity of liver and cecal lesions between the boric acid-supplemented group and the positive-challenged control group.
  • Boric acid did not demonstrate efficacy in preventing or reducing histomoniasis disease severity.

Conclusions:

  • Dietary boric acid at 0.2% concentration was not efficacious in preventing or reducing histomoniasis in turkeys under the experimental conditions.
  • Further research may be needed to explore alternative concentrations or compounds for histomoniasis chemoprophylaxis.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...